Next Phase Newsletter

A biotechnology company is dedicated to the development of genetic detection platforms incorporated with microarrays, Next Generation Sequencing (NGS) and big data analysis for health informatics. The core services of the firm lie upon five areas within reproductive medicine (prenatal/postnatal testing), population medicine, medical oncology, liver DNA methylation test, and scientific research services.

The firm is looking for co-development and in-licensing opportunities that are a fit for their current pipelines/business areas and is open to equity investments on a case-by-case basis. For equity investments, the check size is usually under $10M, ranging between $2M – $10M. The firm is interested in opportunities globally.

The firm looks for assets that align with their current pipelines and core services. Interested areas include in-vitro diagnostics, oncology therapeutics, reproductive and women’s health related technologies. The firm is open to working with companies in different phases of development.There are no specific requirements for the company and the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2020 and based in the US is seeking opportunities in the medical devices and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with initial check sizes between 1 – 3 million USD. The firm prefers to lead/co-lead the financing rounds but is open to co-investing. The firm is focused on companies located in North America and Israel.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, The firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises.

The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A corporate venture subsidiary of a pharmaceutical company is looking to provide equity capital to seed and venture stage companies in the life science space, and invests across North America & Europe. The firm is looking to provide companies with $5 million over the lifetime of the investment.

The firm is currently looking for novel therapeutics, platform technologies, diagnostics, and vaccines. The firm is interested in novel drugs in broad disease areas including neuroscience (particularly neurodegeneration), immunology, inflammation, and rare disease, as well as diagnostics for neurodegenerative disorders. Current platform technology areas of interest include regenerative medicine, synthetic biology, microbiome, gene therapy, and nucleic acid medicine.

The firm strongly prefers that the company has a strong management team with experience in the industry. The firm historically has only invested as a co-investor although they are capable and looking to take a lead position if the correct opportunity arises. The firm is looking to allocate to companies that will eventually be able to partner long term with its parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Kendall Sq. Cambridge, MA, November 30th, 2023 — Life Science Nation (LSN), the visionary force behind the globally acclaimed Redefining Early Stage Investments (RESI) Conference Series, is thrilled to announce a strategic collaboration with Biocat, headquartered in Barcelona, Catalonia, Spain, and Biotechgate, Zurich, Switzerland. Biocat, a catalyzing organization dedicated to transforming the BioRegion of Catalonia into a premier life sciences and health innovation ecosystem in Europe, and Biotechgate, a pioneer in curating and marketing a global business development database tailored for the life science industry, join forces with LSN to bring the RESI global matching platform back to Europe.

The RESI Conference Series has been instrumental in connecting healthcare startups with capital investors, co-development partners, and licensing opportunities worldwide. LSN has a track record of assisting over 400 startups in raising over $5 billion through its investor database, entrepreneurial education, and RESI international partnering events. The LSN partner network, comprising ten categories of investors and licensing partners, actively seeks early-stage innovations in drugs, devices, diagnostics, and digital health for investment portfolio and product pipeline development.

The Power of RESI Partnering

The RESI Partnering platform is a dynamic tool designed to match attendees based on sector, indication, and development phase and is central to the RESI Conference Series. This innovative approach eliminates most ill-fitting meetings, ensuring startups engage with the right investors and licensing partners who align with their specific needs and goals. RESI partnering events run five times annually at life science centers worldwide. They facilitate fundraising CEOs and scientist-entrepreneurs to get out of their local region and into the international market, dramatically increasing the number of potential partners in their pipeline. Fundraising is a numbers game; a startup cannot succeed with one or two conferences yearly. LSN’s startups seek seed funding up to 2M, Series A, 2M-10M, and Series B, 10M-50M. As part of their global partnering campaign initiative, startup companies leverage RESI as a strategic launchpad to meet national and international investors and licensing partners.

“Biocat is unique in Europe because they get it; they understand that shining an international light on their startups and getting them into capital and licensing arrangements early builds the ecosystem’s future,” says Dennis Ford, CEO of Life Science Nation.

Robert Fabregat, CEO of Biocat, said, “LSN has developed a buy-side network that will bring tens of millions of Euros into the BioRegion. Biocat is confident that our rich life science technology ecosystem will capture the attention of global investors and licensing partners and enhance BioRegion’s global footprint.”

Patrik Frei, CEO of Biotechgate, stated, “The Catalan BioRegion, like many others in the European market, is not getting enough of the early-stage investor attention they deserve. Now, startups can attend RESI Europe Barcelona, meet LSN’s global partners, and plug into international RESI events in and outside Europe.”

About RESI Conference Series

RESI is a well-established go-to partnering event series for international scientist-entrepreneurs and fundraising CEOs. It offers a dynamic interactive format featuring one day of face-to-face meetings and two days of global virtual partnering. The RESI Conference Series spans North America, Europe, and Asia, receiving support from governmental agencies, regional international tech hubs, incubators, and accelerators. The 2024 RESI partnering events are scheduled as follows: RESI JPM in San Francisco on January 9th, RESI South Atlanta on March 25th, RESI Europe Barcelona on June 17th, RESI Boston on September 25th, and RESI Asia (location and partner TBD) in November.

About Life Science Nation (LSN)

Life Science Nation (LSN) created the globally recognized Redefining Early Stage Investments (RESI) Conference Series. LSN’s mission is to connect early-stage life science companies with investors and strategic partners, ultimately fostering innovation and driving advancements in the life sciences industry.

About Biocat

Biocat is a strategic stakeholder and catalyst for promoting, transforming and projecting the Catalan life sciences and health innovation ecosystem, known as the BioRegion of Catalonia. It was established in 2006 as a public-private foundation at the behest of the Government of Catalonia and the Barcelona City Council to identify the needs of the BioRegion and implement a strategy and action plan to maximize the economic and social impact of the sector.

About Biotechgate

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 69,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Startups affiliated with a tech hub such an incubator, accelerator, university, non-profit, or government agency are eligible for up to $600 off tickets to RESI JPM, January 9 – 11th, in San Francisco. To get access to a unique discount code, tech hubs or startups affiliated with tech hubs must reach out to Erika Wu at e.wu@lifesciencenation.com 

Tech hubs are also eligible to save 50% off all sponsorship levels at RESI. This is a great opportunity to showcase your startups’ technologies, host a workshop, be featured in LSN’s Next Phase and Tech Hub newsletters, and sell services at an exhibition booth. 

Don’t miss your chance to get access to: 

1. Networking Opportunities  
2. Access to New Technologies  
3. Deal Flow Generation  
4. Early Market Trends and Insights  
5. Investor Engagement  
6. Brand Visibility  
7. Learning and Education from LSN staff and sponsor 
   
   Tech hubs currently registered for RESI JPM 2024 – Sign Up Here: 

RESI JPM 2024 will occur via a hybrid format, with January 9th being in-person at the Marine’s Memorial Hotel in San Francisco, and the 10th and 11th with virtual partnering only. We are expecting 500+ early-stage life science investors and 500+ startups at the upcoming RESI. Check out who’s currently registered. 

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

In the dynamic, highly competitive life science arena, a startup company must have its story straight and act together. Understanding that effective communication is the crux of a successful investor and licensing partner campaign. Life science startup companies face the unique challenge of distilling complex ideas into digestible messages for their target audience. In this context, a clear and concise tagline and elevator pitch seamlessly integrated into the one-page data sheet, two-page executive summary, and 10-12-page pitch deck cannot be underestimated. The tagline and elevator pitch you develop for your startup are a potent tool, serving as the linchpin for all your present and future marketing endeavors. The tagline and elevator pitch anchor all your branding and messaging. These two entities are not slogans, they should be viewed in the context that if the right person read them, they would want to have a meeting with you.

LSN Has Developed a Process for the Continuity of Messaging

Life science startups often deal with intricate scientific concepts and advanced technologies. Communicating these complexities to a target audience, including investors, potential collaborators, and licensing partners, requires a delicate balance. A concise tagline is a beacon of clarity, distilling the company’s core purpose and value proposition into a few impactful words. This clarity is essential for effective communication and builds trust and credibility. A good tagline is hard to craft but easy to identify, requiring multiple iterations. Companies will frequently end on a tagline that is partway there, not realizing the difference that more work can make. This is the difference between a tagline such as ‘novel robotic platform to treat cancer’ and ‘Advancing Localized Cancer Interventions with Self-driving Robotic Platform’ – one tagline seems to provide a good amount of detail, while the other is clearly much more detailed but still concise. A well-crafted tagline remains an invaluable asset in the arsenal of marketing materials for startups striving to make a lasting impact.

Life Science Nation announced a Tagline Competition Contest. The top three taglines to receive complimentary registrations to our upcoming partnering conference, RESI JPM in San Francisco at the Marine’s Memorial Club & Hotel on January 9. The staff at LSN evaluated each submission based on clarity, level of detail, and conciseness when considering the top three. Thank you to the companies that applied. LSN evaluated close to 100 submissions. The winners are:

Tagline Competition Contest Winners
	Flexperc Medical
	Advancing Localized Cancer Interventions with Self-driving Robotic Platform
	Nesa Medtech
	Transform women’s health by developing a scarless, image-guided surgical solution to treat uterine fibroids.
	Inherent Biosciences
	Pioneering Epigenetic Diagnostics in Reproductive Health

Congratulations to the winners! We look forward to seeing you at RESI JPM!

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
Joey Wong, Senior Investor Research Analyst, Hong Kong BD, LSN

During October and November, LSN’s team traveled to Asia to meet regional partners, explore RESI Asia’s potential,  and, most importantly, deliver LSN Entrepreneurial Bootcamps to Hong Kong region startups in collaboration with Hong Kong Science and Technology Park (HKSTP) and Life Science Incubator.

LSN partnered up with the HKSTP team and tailored the program to fit the needs of about 75 startup, primarily members of HKSTP’s Incubio program, focusing on tactical advice and actionable steps for launching your company in the life science and healthcare industry and how to execute a capital fundraising and licensing partner campaign on a global scale. The two-day boot camp from October 19 to 20^th attracted attendees from various backgrounds, including university researchers, scientists, physicians, and all who are actively building a new generation of startup companies. The team discussed the value of delivering a compelling story to potential partners that reveals who the founder and team are and what factors brought them together. The LSN team provided interactive exercises to encourage attendees to enhance their “problem/solution/market” pitch decks with a compelling narrative and create taglines and elevator pitches that net out the value of their product while making it easy to understand without dumbing down the message.

On the second day of the boot camp, the LSN team met one-on-one with selected companies to provide consultations on their current fundraising materials, partnering strategies, and critical business development objectives. The great technologies that we were able to review during these two days were a testament to the impressive scientific research talent in Hong Kong. The LSN platform matches global startups with international investors and licensing partners who seek them by using the LSN investor and licensing partner database or attending one of the RESI conferences LSN holds worldwide. Most investors and licensing partners are global and mainly focus on the team and technology rather than their location. Bringing LSN’s global perspective that partnering is fundamentally a numbers game, and you need to leave your region and meet the players that fit your stage of development and product is the straightest line to successful partnering.

Next up was the Life Science Incubator in Singapore on October 24^th. Once again, we meet with dynamic entrepreneurs who are creating new products that will significantly impact life science. The boot camp was designed to be more hands-on with one-on-one interaction where the LSN team shared insights based on our collective experiences working with clients and addressed questions about how to find, vet, and approach the investors and licensing partners that fit your startup. The boot camp culminated with attendees getting practice doing elevator pitches, followed by the LSN team providing feedback and coaching.

In addition to the boot camp, we attended the Asia Health and Life Sciences Innovation and Cooperation Summit (AHLSICS) organized by Ask Health Asia. The summit featured an impressive lineup of senior executives from key industry players, government organizations, and investment firms through a series of thoughtfully curated and highly informative panels and keynote presentations, focusing on the landscape and environment of innovation and market opportunities in Asia.

It was a pleasure for the LSN team to meet with many life science healthcare innovators in Hong Kong and Singapore, along with several key players and government organizations. We were highly impressed by the vibrant startup ecosystem, cutting-edge infrastructures, and the active role of the governments in providing substantial, practical support for tech transfer, startup funding, and R&D. The trip was immensely fruitful in helping LSN map the landscape of Hong Kong and Singapore’s life science and healthcare ecosystem, solidifying LSN’s position to support local innovators to expand their business to a global scale. We want to extend our gratitude to those who met with us or hosted us during the trip, and we look forward to collaborating more in the future.

LSN’s The Entrepeniual Educational series, which features 16 novel entrepreneurial courses, is designed for entrepreneurs who are starting to plan for their fundraising and licensing partner search. The educational programs focus on getting your company’s marketing collateral ready, followed by how to manage an efficient fundraising campaign to maximize the probability of getting a second meeting, which can greatly determine an early-stage entity’s success when moving from their regional environment to the global competitive landscape. If you have any questions about hosting an LSN education course please contact Karen Deyo, VP of Product, Israel BD, LSN.